DE122004000039I2 - Gaba und L-Glutaminsa}re analoga zur Behandlung der Epilepsie - Google Patents

Gaba und L-Glutaminsa}re analoga zur Behandlung der Epilepsie

Info

Publication number: DE122004000039I2
Authority: DE; Germany
Prior art keywords: treatment; compound; glutaminsa; analoga; gaba
Prior art date: 1992-05-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

DE1993630949

Other languages

English (en)

Other versions

DE69330949T2 (de

DE122004000039I1 (de

DE69330949D1 (de

Inventor

Richard B Silverman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Northwestern University

Original Assignee

Northwestern University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-20

Filing date

1993-05-18

Publication date

2006-06-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25388336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122004000039(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-05-18 Application filed by Northwestern University filed Critical Northwestern University

2006-05-18 Publication of DE122004000039I1 publication Critical patent/DE122004000039I1/de

2006-06-29 Publication of DE122004000039I2 publication Critical patent/DE122004000039I2/de

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
- C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
- C07C247/12—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Anesthesiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Steroid Compounds (AREA)
Enzymes And Modification Thereof (AREA)

DE1993630949 1992-05-20 1993-05-18 Gaba und L-Glutaminsa}re analoga zur Behandlung der Epilepsie Active DE122004000039I2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US88608092A	1992-05-20	1992-05-20
PCT/US1993/004680 WO1993023383A1 (en)	1992-05-20	1993-05-18	Gaba and l-glutamic acid analogs for antiseizure treatment

Publications (2)

Publication Number	Publication Date
DE122004000039I1 DE122004000039I1 (de)	2006-05-18
DE122004000039I2 true DE122004000039I2 (de)	2006-06-29

Family

ID=25388336

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE1993630949 Active DE122004000039I2 (de)	1992-05-20	1993-05-18	Gaba und L-Glutaminsa}re analoga zur Behandlung der Epilepsie
DE69330949T Expired - Lifetime DE69330949T2 (de)	1992-05-20	1993-05-18	Gaba und l-glutaminsaüre analoga zur behandlung der epilepsie

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE69330949T Expired - Lifetime DE69330949T2 (de)	1992-05-20	1993-05-18	Gaba und l-glutaminsaüre analoga zur behandlung der epilepsie

Country Status (21)

Country	Link
EP (1)	EP0641330B1 (de)
JP (2)	JP3856816B2 (de)
KR (1)	KR950701625A (de)
AT (1)	ATE207052T1 (de)
AU (1)	AU677008B2 (de)
CA (1)	CA2134674C (de)
CZ (1)	CZ286106B6 (de)
DE (2)	DE122004000039I2 (de)
DK (1)	DK0641330T3 (de)
ES (1)	ES2165857T3 (de)
FI (1)	FI945426A0 (de)
HU (2)	HU222776B1 (de)
LU (1)	LU91112I2 (de)
NL (1)	NL300164I2 (de)
NO (1)	NO944370L (de)
NZ (1)	NZ253459A (de)
PT (1)	PT641330E (de)
RU (2)	RU94046105A (de)
SG (1)	SG48288A1 (de)
SK (1)	SK283281B6 (de)
WO (1)	WO1993023383A1 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL113052A0 (en) *	1994-03-23	1995-06-29	Rhone Poulenc Rorer Sa	Recombinant viruses, their preparation and their use in gene therapy
DK0804182T3 (da) *	1994-07-27	2002-09-09	Warner Lambert Co	Anvendelse af gabapentin ved behandling af angst og panik
US5792796A (en) *	1994-07-27	1998-08-11	Warner-Lambert Company	Methods for treating anxiety and panic
US5616793A (en) *	1995-06-02	1997-04-01	Warner-Lambert Company	Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US5637767A (en) *	1995-06-07	1997-06-10	Warner-Lambert Company	Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
US6372792B1 (en) *	1996-04-26	2002-04-16	Guy Chouinard	Method for treating anxiety, anxiety disorders and insomnia
EP0934061B3 (de)	1996-07-24	2015-01-21	Warner-Lambert Company LLC	Isobutylgaba und dessen derivate zur schmerzbehandlung
DE69737719D1 (de) *	1996-10-23	2007-06-21	Warner Lambert Co	Substituierte gamma-aminobuttersäurederivate als arzneimittel
WO1999008670A1 (en) *	1997-08-20	1999-02-25	Guglietta, Antonio	Gaba analogs to prevent and treat gastrointestinal damage
BR9812162A (pt)	1997-09-08	2000-07-18	Warner Lambert Co	Composições analgésicas compreendendo compostos antiepiléticos e métodos para o uso das mesmas
KR100602047B1 (ko) *	1998-05-15	2006-07-19	워너-램버트 캄파니 엘엘씨	감마-아미노부티르산 유도체의 안정화된 제약 제제 및그의 제조 방법
KR100697734B1 (ko) *	1998-10-16	2007-03-22	워너-램버트 캄파니 엘엘씨	조증 및 양극성 장애 치료용 제약 조성물
WO2000031020A1 (en)	1998-11-25	2000-06-02	Warner-Lambert Company	Improved gamma amino butyric acid analogs
US6992109B1 (en) *	1999-04-08	2006-01-31	Segal Catherine A	Method for the treatment of incontinence
HUP0200738A3 (en) *	1999-04-08	2003-03-28	Warner Lambert Co	Method of the treatment of incontinence
US7164034B2 (en)	1999-06-10	2007-01-16	Pfizer Inc.	Alpha2delta ligands for fibromyalgia and other disorders
ES2317839T3 (es) *	1999-06-10	2009-05-01	Warner-Lambert Company Llc	Acidos 3-propil gamma-aminobutiricos monosustituidos.
US6642398B2 (en)	1999-06-10	2003-11-04	Warner-Lambert Company	Mono-and disubstituted 3-propyl gamma-aminobutyric acids
WO2002022622A2 (en)	2000-09-13	2002-03-21	Georgetown University	Synthesis of 2-hydroxymethylglutamic acid and congeners thereof
AU2002211863A1 (en)	2000-10-06	2002-04-15	Xenoport, Inc.	Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
WO2002032376A2 (en)	2000-10-06	2002-04-25	Xenoport, Inc.	Bile-acid conjugates for providing sustained systemic concentrations of drugs
RU2202538C2 (ru) *	2001-05-04	2003-04-20	Савельев Евгений Александрович	Способ получения 4-аминомасляной кислоты
US6462084B1 (en) *	2001-05-14	2002-10-08	Brookhaven Science Associates, Llc	Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
KR20070108282A (ko)	2001-06-11	2007-11-08	제노포트 인코포레이티드	감소된 독성을 가진 ｇａｂａ 유사체 프로드러그의 구강투여용 투여 형태물
US8048917B2 (en)	2005-04-06	2011-11-01	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en)	2001-06-11	2004-11-16	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en)	2001-06-11	2007-06-19	Xenoport, Inc.	Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7186855B2 (en)	2001-06-11	2007-03-06	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
EP1412324A4 (de)	2001-06-11	2004-09-29	Xenoport Inc	Aminosäurekonjugate, die anhaltende systemische konzentrationen von gaba-analoga ergeben
EP1485082A4 (de)	2002-02-19	2009-12-30	Xenoport Inc	Syntheseverfahren für prodrugs von 1-acyl-alkyl derivaten und ihre zusammensetzungen
RU2220131C2 (ru) *	2002-02-28	2003-12-27	Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации"	Соли 4-амино-3-фенилбутановой кислоты и лекарственное средство, обладающие антиишемической гипотензивной, противоаритмической, ноотропной и антигипоксической активностью
WO2003080588A1 (en)	2002-03-20	2003-10-02	Xenoport	Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
US20030225149A1 (en)	2002-04-30	2003-12-04	Blazecka Peter G.	Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
US7183259B2 (en)	2002-05-17	2007-02-27	Xenoport	Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US7419981B2 (en)	2002-08-15	2008-09-02	Pfizer Inc.	Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7071339B2 (en)	2002-08-29	2006-07-04	Warner Lambert Company Llc	Process for preparing functionalized γ-butyrolactones from mucohalic acid
AU2003297927A1 (en)	2002-12-11	2004-06-30	Xenoport, Inc.	Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
EP2196201A3 (de)	2002-12-13	2010-12-08	Warner-Lambert Company LLC	Kombination von einem alpha-2-delta Ligand mit einem pdev Inhibitor oder einem muscarinischen Antagonisten zurBehandlung von Symptomen der unteren Harnwege
CA2451267A1 (en) *	2002-12-13	2004-06-13	Warner-Lambert Company Llc	Pharmaceutical uses for alpha2delta ligands
WO2004054566A1 (en)	2002-12-13	2004-07-01	Warner-Lambert Company Llc	Pregabalin derivatives for the treatment of fibromyalgia and other disorders
CA2537837A1 (en)	2003-09-11	2005-03-24	Xenoport, Inc.	Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
ATE449633T1 (de)	2003-09-12	2009-12-15	Pfizer	Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
WO2005027850A2 (en)	2003-09-17	2005-03-31	Xenoport, Inc.	Treating or preventing restless legs syndrome using prodrugs of gaba analogs
ATE516801T1 (de)	2003-10-14	2011-08-15	Xenoport Inc	Kristalline form eines gamma-aminobuttersäure- analogons
WO2005060968A1 (en)	2003-12-11	2005-07-07	Sepracor Inc.	Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
AU2005301970B2 (en)	2004-11-04	2011-06-02	Arbor Pharmaceuticals, Llc	Gabapentin prodrug sustained release oral dosage forms
EP1820502A1 (de)	2006-02-10	2007-08-22	Laboratorios Del Dr. Esteve, S.A.	Wirkstoffzusammensetzungen enthaltend Azolycarbinolderivate
US20080153888A1 (en)	2006-12-22	2008-06-26	Recordati Ireland Limited	Alpha-2-delta ligand/nsaid therapeutic treatment of lower urinary tract disorders
WO2009081208A1 (en) *	2007-12-26	2009-07-02	Generics [Uk] Limited	Processes to pregabalin
WO2009094577A2 (en)	2008-01-25	2009-07-30	Xenoport, Inc.	Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2250148B1 (de)	2008-01-25	2016-08-17	XenoPort, Inc.	Kristalline form von kalziumsalzen von (3s)-aminomethyl-5-methylhexansäuren und anwendungsverfahren
TWI380812B (zh)	2008-01-25	2013-01-01	Xenoport Inc	（３ｓ）-胺甲基-５-甲基己酸前藥之晶形及使用方法
EP2110372A1 (de)	2008-04-16	2009-10-21	Chemo Ibérica, S.A.	Zwischenprodukte für die Herstellung von Pregabalin und deren Herstellungsverfahren
EP2116539A1 (de)	2008-04-25	2009-11-11	Laboratorios Del. Dr. Esteve, S.A.	1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon
EP2123626A1 (de)	2008-05-21	2009-11-25	Laboratorios del Dr. Esteve S.A.	Duloxetin-Kokristalle und Kokristallbildner für Schmerzbehandlung
AU2009302241B2 (en)	2008-10-08	2015-10-29	Xgene Pharmaceutical Inc.	GABA conjugates and methods of use thereof
RU2393855C1 (ru) *	2008-12-29	2010-07-10	Общество С Ограниченной Ответственностью "Валента-Интеллект"	Средство, обладающее анксиолитической и церебропротекторной активностью, уменьшающее влечение к алкоголю
ES2362913B1 (es)	2009-12-24	2012-05-24	Moehs Iberica S.L.	Nuevo método para la preparación de (s)-pregabalina.
EP2353598A1 (de)	2010-02-04	2011-08-10	Laboratorios Del. Dr. Esteve, S.A.	Sigma-Liganden zur Anwendung in der Vorbeugung und/oder Behandlung von postoperativem Schmerz
EP2353591A1 (de)	2010-02-04	2011-08-10	Laboratorios Del. Dr. Esteve, S.A.	Sigma-Liganden zur Verstärkung der analgesischen Wirkung von Opioden und Opiaten bei postoperativem Schmerz und zur Schwächung der Abhängigkeit davon
SG10201502026XA (en)	2010-03-18	2015-05-28	Daiichi Sankyo Co Ltd	Cycloalkyl-substituted imidazole derivative
CA2793523C (en)	2010-03-18	2015-05-05	Daiichi Sankyo Company, Limited	Cyclopropanecarboxylic acid derivative
EP2383255A1 (de)	2010-04-28	2011-11-02	Lacer, S.A.	Neue Verbindungen, deren Synthese und Verwendung bei der Schmerzbehandlung
EP2388005A1 (de)	2010-05-21	2011-11-23	Laboratorios Del. Dr. Esteve, S.A.	Sigma-Liganden zur Vorbeugung und/oder Behandlung von Erbrechen infolge von Chemotherapie oder Strahlentherapie
AU2011283462B9 (en)	2010-07-30	2014-09-18	Toray Industries, Inc.	Therapeutic agent or prophylactic agent for neuropathic pain
EP2415460A1 (de)	2010-08-03	2012-02-08	ratiopharm GmbH	Orale Darreichungsform von Pregabalin
EP2415471A1 (de)	2010-08-03	2012-02-08	Laboratorios Del. Dr. Esteve, S.A.	Verwendung von Sigmaliganden bei opioidinduzierter Hyperalgesie
US8212072B2 (en)	2010-08-13	2012-07-03	Divi's Laboratories, Ltd.	Process for the preparation of pregabalin
EP2524694A1 (de)	2011-05-19	2012-11-21	Laboratorios Del. Dr. Esteve, S.A.	Verwendung von Sigmaliganden bei Schmerz im Zusammenhang mit Typ-2-Diabetes
EP2527319A1 (de)	2011-05-24	2012-11-28	Laboratorios Del. Dr. Esteve, S.A.	Kristalline Formen von Pregabalin und Co-Formern zur Behandlung von Schmerzen
WO2013100873A1 (en)	2011-12-19	2013-07-04	Mahmut Bilgic	Pharmaceutical formulation of pregabalin (particle size 300-2500 micrometer)
ES2423254B1 (es)	2012-02-15	2014-03-26	Laboratec, S.L.	Composición farmacéutica para el tratamiento de incontinencia urinaria y enuresis
US9066853B2 (en)	2013-01-15	2015-06-30	Warsaw Orthopedic, Inc.	Clonidine compounds in a biodegradable fiber
US10130715B2 (en)	2013-01-28	2018-11-20	Hector L. Lopez	Methods of improving tolerability, pharmacodynamics, and efficacy of β-alanine and use therefor
CA2933511A1 (en)	2013-12-17	2015-06-25	Laboratorios Del Dr. Esteve, S.A.	Serotonin-norepinephrine reuptake inhibitors (snris) and sigma receptor ligands combinations
CA2933057A1 (en)	2013-12-17	2015-06-25	Laboratorios Del Dr. Esteve, S.A.	Gabapentinoids and sigma receptor ligands combinations
WO2016075082A1 (en)	2014-11-10	2016-05-19	Sandoz Ag	Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam
EP3793974A4 (de)	2018-05-14	2022-05-04	Xgene Pharmaceutical Inc	Kristalline formen von 1-(acyloxy)-alkylcarbamat-wirkstoffkonjugaten von naproxen und pregabalin
DE202018105573U1 (de)	2018-09-27	2018-10-19	Laboratec	Pharmazeutische Zusammensetzung zur Behandlung der Harninkontinenz und Enuresis
EP4281059A4 (de)	2021-01-22	2025-01-15	Egis Gyógyszergyár Zrt.	Topische formulierung mit modifizierten phospholipidverbindungen
HU231397B1 (hu)	2021-01-22	2023-06-28	Egis Gyógyszergyár Zrt.	Pregabalint tartalmazó topikális gyógyszerkészítmény

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4840460B1 (de) *	1969-02-05	1973-11-30
US4173541A (en) *	1978-06-05	1979-11-06	Cincinnati Milacron Chemicals Inc.	Polynuclear hindered phenols and stabilized organic materials containing the phenols
US4322440A (en) *	1980-06-25	1982-03-30	New York University	Anticonvulsive compositions and method of treating convulsive disorders
US4479005A (en) *	1982-12-16	1984-10-23	The Dow Chemical Company	Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids
US4771038A (en) *	1986-01-21	1988-09-13	Ici Americas Inc.	Hydroxamic acids
US4814342A (en) *	1986-10-31	1989-03-21	Pfizer Inc.	Nor-statine and nor-cyclostatine polypeptides
KR930003864B1 (ko) *	1990-10-19	1993-05-14	한국과학기술연구원	d-2-(6-메톡시-2-나프틸)-프로피온산의 제조방법
WO1992009560A1 (en) *	1990-11-27	1992-06-11	Northwestern University	Gaba and l-glutamic acid analogs for antiseizure treatment
US5198548A (en) *	1992-01-30	1993-03-30	Warner-Lambert Company	Process for the preparation of D(-) and L(+)-3,3-diphenylalanine and D(-) and L(+)-substituted 3,3-diphenylalanines and derivatives thereof

1993
- 1993-05-18 ES ES93925173T patent/ES2165857T3/es not_active Expired - Lifetime
- 1993-05-18 FI FI945426A patent/FI945426A0/fi not_active Application Discontinuation
- 1993-05-18 JP JP50380794A patent/JP3856816B2/ja not_active Expired - Lifetime
- 1993-05-18 RU RU94046105/04A patent/RU94046105A/ru unknown
- 1993-05-18 DK DK93925173T patent/DK0641330T3/da active
- 1993-05-18 AT AT93925173T patent/ATE207052T1/de active
- 1993-05-18 EP EP93925173A patent/EP0641330B1/de not_active Expired - Lifetime
- 1993-05-18 DE DE1993630949 patent/DE122004000039I2/de active Active
- 1993-05-18 SG SG1996008718A patent/SG48288A1/en unknown
- 1993-05-18 SK SK1395-94A patent/SK283281B6/sk not_active IP Right Cessation
- 1993-05-18 AU AU43794/93A patent/AU677008B2/en not_active Ceased
- 1993-05-18 RU RU96124481A patent/RU2140901C1/ru active
- 1993-05-18 KR KR1019940704158A patent/KR950701625A/ko not_active Withdrawn
- 1993-05-18 HU HU9702482A patent/HU222776B1/hu active IP Right Grant
- 1993-05-18 CA CA002134674A patent/CA2134674C/en not_active Expired - Lifetime
- 1993-05-18 DE DE69330949T patent/DE69330949T2/de not_active Expired - Lifetime
- 1993-05-18 NZ NZ253459A patent/NZ253459A/en not_active IP Right Cessation
- 1993-05-18 HU HU9403310A patent/HU222339B1/hu active Protection Beyond IP Right Term
- 1993-05-18 WO PCT/US1993/004680 patent/WO1993023383A1/en not_active Ceased
- 1993-05-18 PT PT93925173T patent/PT641330E/pt unknown
- 1993-05-18 CZ CZ19942849A patent/CZ286106B6/cs not_active IP Right Cessation
1994
- 1994-11-16 NO NO944370A patent/NO944370L/no unknown
2004
- 2004-03-16 JP JP2004075406A patent/JP4297814B2/ja not_active Expired - Lifetime
- 2004-10-06 LU LU91112C patent/LU91112I2/fr unknown
- 2004-11-22 NL NL300164C patent/NL300164I2/nl unknown

Also Published As

Publication number	Publication date
FI945426A7 (fi)	1994-11-18
KR950701625A (ko)	1995-04-28
JP4297814B2 (ja)	2009-07-15
ATE207052T1 (de)	2001-11-15
EP0641330A4 (de)	1997-05-28
ES2165857T3 (es)	2002-04-01
NO944370L (no)	1994-11-21
EP0641330A1 (de)	1995-03-08
HU9702482D0 (en)	1998-03-02
DE69330949T2 (de)	2002-04-04
HUT71522A (en)	1995-12-28
RU94046105A (ru)	1997-06-20
HU222776B1 (hu)	2003-10-28
JPH07508288A (ja)	1995-09-14
NO944370D0 (no)	1994-11-16
HK1011022A1 (en)	1999-07-02
CA2134674C (en)	2004-12-21
CA2134674A1 (en)	1993-11-25
EP0641330B1 (de)	2001-10-17
NL300164I2 (nl)	2005-02-01
HU9403310D0 (en)	1995-02-28
SK139594A3 (en)	1995-05-10
HU222339B1 (hu)	2003-06-28
SK283281B6 (sk)	2003-05-02
FI945426L (fi)	1994-11-18
JP2004238398A (ja)	2004-08-26
DK0641330T3 (da)	2001-12-03
CZ286106B6 (cs)	2000-01-12
CZ284994A3 (en)	1995-03-15
AU4379493A (en)	1993-12-13
SG48288A1 (en)	1998-04-17
WO1993023383A1 (en)	1993-11-25
NZ253459A (en)	1997-03-24
DE122004000039I1 (de)	2006-05-18
RU2140901C1 (ru)	1999-11-10
DE69330949D1 (de)	2001-11-22
PT641330E (pt)	2002-03-28
JP3856816B2 (ja)	2006-12-13
LU91112I2 (fr)	2004-12-06
NL300164I1 (nl)	2005-01-03
FI945426A0 (fi)	1994-11-18
AU677008B2 (en)	1997-04-10

Publication	Publication Date	Title
DE122004000039I2 (de)	2006-06-29	Gaba und L-Glutaminsa}re analoga zur Behandlung der Epilepsie
ATE139783T1 (de)	1996-07-15	Azasteroide zur behandlung prostatischer hypertrophie, ihre herstellung und verwendung
ATE215078T1 (de)	2002-04-15	Verbessertes verfahren zum herstellen von geschützten 3,4-dihydroxybuttersäure estern
TW265337B (de)	1995-12-11
IL133891A (en)	2003-02-12	Valproenoic acid amide derivatives and pharmaceutical compositions containing them
NZ272015A (en)	1999-07-29	Treatment of insufficiency of central choline functions using a cyclic amide (substituted 1,3-benzoxazin-2-one derivative)
AU515774B2 (en)	1981-04-30	Benzopyran derivatives
LV10235A (lv)	1994-10-20	Jauni esteri to iegusanas panemiens farmaceitiska kompozicija arstesanas metode
ES8707518A1 (es)	1987-08-01	Un procedimiento para preparar nuevos derivados del 1,3-ben-zoxatiol
ATE250027T1 (de)	2003-10-15	Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
ATE186907T1 (de)	1999-12-15	Optisch aktives 1-phenylpyrrolidonderivat und dessen herstellung
ATE264840T1 (de)	2004-05-15	Azetidincarboxamid-derivate zur behandlung von zns störungen
MX9302970A (es)	1994-05-31	Analogos de acido l-glutamico y gaba para tratamiento anti-ataque.
ATE220665T1 (de)	2002-08-15	Azetidincarboxamidderivate zur behandlung von zns-erkrankungen